Exicure (XCUR) Stock Price, News & Analysis

Company Overview

Exicure, Inc. is a biotechnology company that historically focused on developing nucleic acid-based medicines. Its research was built around Spherical Nucleic Acid (SNA) technology, a platform designed to package and deliver short strands of genetic material into cells to influence disease-related biological pathways.

The company’s development programs included investigational treatments for oncology, inflammatory diseases and genetic disorders. Its most prominent candidates included cavrotolimod, an immunotherapy designed to activate the toll-like receptor 9 pathway, and earlier dermatology-focused programs intended to address conditions such as psoriasis and related inflammatory diseases. These candidates were investigational and were not established commercial products.

Exicure was founded in 2011 and was based in the Chicago area. The company entered into research and development collaborations with pharmaceutical partners, including AbbVie, to explore applications of its SNA technology. Public disclosures in subsequent years indicated significant operational and corporate challenges, and information about its ongoing programs, leadership and commercial activities has been limited.

Key Stats

• Today's Range: $1.09 to $1.21
• 50-Day Range: $1.00 to $1.51
• 52-Week Range: $0.94 to $9.48
• Volume: 27,644 shs
• Average Volume: 30,852 shs
• Market Capitalization: $7.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Exicure Stock Analysis - MarketRank™

Exicure scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Exicure has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Exicure has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Exicure has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.22% of the float of Exicure has been sold short.

Short Interest Ratio / Days to Cover

Exicure has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exicure has recently decreased by 46.85%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Exicure does not currently pay a dividend.

Dividend Growth

Exicure does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.41

News Sentiment

Exicure has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Exicure this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Exicure insiders have not sold or bought any company stock.

Percentage Held by Insiders

52.80% of the stock of Exicure is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.82% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:XCUR
• CIK: 1698530
• Web: www.exicuretx.com
• Phone: (847) 673-1707
• Fax: N/A
• Employees: 50
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): ($1.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.95 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -237.91%
• Return on Assets: -61.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.56
• Quick Ratio: 0.56

Sales & Book Value

• Annual Sales: $500 thousand
• Price / Sales: 15.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.62 per share
• Price / Book: 1.85

Miscellaneous

• Outstanding Shares: 6,550,000
• Free Float: 3,090,000
• Market Cap: $7.53 million
• Optionable: Not Optionable
• Beta: 3.64